Gemcitabine has been proved to exert different effects on pancreatic cancer cells in a dose and time dependent manner by inducing different signaling pathways [21, 27], whereas Bmi1 expression can also be affected by such specific signaling molecules [28]. The gene discussed is BMI1; the disease is familial pancreatic carcinoma.